CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Riluzole Oral Suspension
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2024-01-26. Latest FDA row update: 2026-10-01.
FDA lists 4 package records, with companies: EDW PHARMA, EDW PHARMA, INC, EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.). Package NDCs: 70726-0303-1, 70726-0304-1, 70726-0305-1, 70726-0306-1.
FDA shortage reason: Requirements related to complying with good manufacturing practices
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | 70726-0304-1 | Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1) | Available | 2026-10-01 |
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | 70726-0305-1 | Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1) | Available | 2026-10-01 |
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | 70726-0306-1 | Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1) | Available | 2026-10-01 |
| EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | 70726-0303-1 | Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1) | Unavailable | 2026-10-01 |
Source facts
Grouped generic ingredient: Riluzole Oral Suspension · 4 package records
Therapeutic categories: Neurology
Dosage forms: Oral Suspension
Routes: ORAL
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.